[JUVENILE IDIOPATHIC ARTHRITIS].

Area of Science:

• Rheumatology
• Pediatric Immunology
• Genetics

Background:

• Juvenile idiopathic arthritis (JIA) is the most prevalent rheumatic condition in children, frequently leading to disability.
• JIA is characterized by joint inflammation of unknown origin before age 16, persisting over six weeks.
• This condition is not a single entity but a spectrum of disorders with varying immunopathogenesis and clinical presentations.

Purpose of the Study:

• To highlight the importance of understanding JIA pathogenesis for developing improved therapeutic strategies.
• To emphasize the goal of treatments: pain relief, inflammation control, and prevention of irreversible joint damage.
• To underscore the impact of new research on refining JIA classification and treatment approaches.

Main Methods:

• Review of current understanding of JIA immunopathogenesis.
• Analysis of the International League of Associations for Rheumatology (ILAR) classification criteria.
• Evaluation of the role of biological agents in JIA treatment.

Main Results:

• JIA classification into 8 subtypes is evolving with advances in genetics and immunology.
• Research into disease pathogenesis is crucial for advancing JIA treatment.
• Biological agents have demonstrated significant improvements in JIA prognosis.

Conclusions:

• Continued research into JIA pathogenesis is essential for developing targeted and effective therapies.
• The evolving classification of JIA reflects a growing understanding of its complex nature.
• Biological therapies represent a significant advancement in managing JIA, improving patient outcomes and reducing disability.